| 1% | Les prix à la consommation en France augmentent de 1% en Juin 2025- Insee |
|
Accueil > Actualité
Roche: efficacy of Evrysdi in spinal muscular atrophy
(CercleFinance.com) - Roche has announced five-year data confirming the efficacy and safety of Evrysdi (risdiplam) in children with type 1 spinal muscular atrophy.
At the end of the fifth year, 91% of treated children were alive, 81% without permanent ventilation, and 59% could sit without support. Seven children could stand and some could walk with support. Evrysdi helped maintain or improve motor skills, swallowing and tube-free feeding, the laboratory points out. Adverse events fell by 66% between the first and last years, with fewer hospitalizations. Evrysdi is the only non-invasive oral treatment for SMA, developed by Roche in collaboration with the SMA Foundation and PTC Therapeutics. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
18/07/2025 18:11
Rocherefus de la FDA pour une nouvelle indication de Columvi 18/07/2025 17:31 EDFcontrat pour alimenter les sites de Kem One pendant 10 ans 18/07/2025 17:06 Ericssonla 'culture inclusive' saluée par Bloomberg Green 18/07/2025 16:55 Nissandébute les concertations et prépare la transition post-Oppama 18/07/2025 16:45 Netflixprises de bénéfices appuyées après les résultats trimestriels 18/07/2025 16:27 Siemenstrains à batterie pour Regiobahn en Allemagne Tous les articles sociétés |
